 Sanchayita Sen
Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shock, Hemorrhagic | 6 | 2023 | 199 | 2.590 |
Why?
| | Blood Coagulation Disorders | 5 | 2023 | 197 | 1.350 |
Why?
| | Proteomics | 6 | 2023 | 836 | 1.350 |
Why?
| | Neutrophils | 10 | 2022 | 1176 | 1.000 |
Why?
| | Brain Injuries, Traumatic | 3 | 2023 | 301 | 0.880 |
Why?
| | Hypocalcemia | 1 | 2023 | 31 | 0.860 |
Why?
| | Serpins | 1 | 2022 | 25 | 0.830 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2022 | 83 | 0.830 |
Why?
| | Complement C4 | 1 | 2022 | 25 | 0.810 |
Why?
| | Pericytes | 1 | 2022 | 24 | 0.800 |
Why?
| | Balloon Occlusion | 1 | 2022 | 26 | 0.790 |
Why?
| | Neutrophil Activation | 6 | 2006 | 94 | 0.790 |
Why?
| | Blast Injuries | 1 | 2022 | 42 | 0.790 |
Why?
| | Interleukin-8 | 1 | 2022 | 237 | 0.770 |
Why?
| | Hemolysis | 1 | 2022 | 146 | 0.770 |
Why?
| | Arginine | 1 | 2022 | 238 | 0.750 |
Why?
| | Interleukin-10 | 1 | 2022 | 299 | 0.720 |
Why?
| | Astrocytes | 1 | 2022 | 162 | 0.720 |
Why?
| | Saline Solution, Hypertonic | 4 | 2022 | 53 | 0.640 |
Why?
| | Fibrinolysis | 2 | 2022 | 158 | 0.630 |
Why?
| | Endovascular Procedures | 1 | 2022 | 269 | 0.610 |
Why?
| | Brain Injuries | 1 | 2022 | 461 | 0.570 |
Why?
| | Proto-Oncogene Proteins c-hck | 1 | 2016 | 3 | 0.550 |
Why?
| | Lysophosphatidylcholines | 1 | 2016 | 30 | 0.540 |
Why?
| | Protein Kinase C | 2 | 2016 | 273 | 0.530 |
Why?
| | NADPH Oxidases | 1 | 2016 | 120 | 0.520 |
Why?
| | Protein Kinase C-delta | 1 | 2016 | 70 | 0.510 |
Why?
| | Tissue Plasminogen Activator | 2 | 2023 | 225 | 0.490 |
Why?
| | NF-kappa B | 9 | 2017 | 638 | 0.440 |
Why?
| | Multiple Organ Failure | 3 | 2022 | 146 | 0.440 |
Why?
| | Cytokines | 10 | 2022 | 1840 | 0.440 |
Why?
| | Wounds and Injuries | 2 | 2022 | 745 | 0.430 |
Why?
| | Protein C | 2 | 2023 | 45 | 0.420 |
Why?
| | Cell Membrane | 1 | 2016 | 680 | 0.410 |
Why?
| | Thrombelastography | 4 | 2023 | 180 | 0.400 |
Why?
| | Swine | 3 | 2023 | 700 | 0.390 |
Why?
| | Calcium | 3 | 2023 | 1104 | 0.370 |
Why?
| | Hemorrhage | 3 | 2022 | 620 | 0.350 |
Why?
| | Resuscitation | 2 | 2022 | 252 | 0.340 |
Why?
| | Endothelial Cells | 3 | 2023 | 681 | 0.330 |
Why?
| | Enzyme Activation | 7 | 2016 | 785 | 0.320 |
Why?
| | Epithelial Cells | 3 | 2017 | 950 | 0.300 |
Why?
| | Histones | 2 | 2022 | 535 | 0.300 |
Why?
| | Receptors, Immunologic | 2 | 2005 | 201 | 0.280 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 107 | 0.260 |
Why?
| | Inflammation | 5 | 2023 | 2478 | 0.260 |
Why?
| | Signal Transduction | 7 | 2017 | 4509 | 0.260 |
Why?
| | Receptors, Cell Surface | 2 | 2004 | 355 | 0.250 |
Why?
| | Lipopolysaccharides | 6 | 2006 | 821 | 0.250 |
Why?
| | Membrane Glycoproteins | 2 | 2004 | 430 | 0.240 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2005 | 54 | 0.240 |
Why?
| | Proto-Oncogene Proteins | 3 | 2005 | 608 | 0.240 |
Why?
| | Oxidants | 2 | 2004 | 112 | 0.230 |
Why?
| | Lung | 4 | 2017 | 3558 | 0.220 |
Why?
| | Phosphorylation | 5 | 2016 | 1569 | 0.220 |
Why?
| | Protein Transport | 4 | 2016 | 395 | 0.220 |
Why?
| | Humans | 18 | 2023 | 114624 | 0.220 |
Why?
| | Animals | 14 | 2023 | 31695 | 0.210 |
Why?
| | Thrombophilia | 1 | 2023 | 67 | 0.210 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2016 | 445 | 0.210 |
Why?
| | Arginase | 1 | 2022 | 27 | 0.210 |
Why?
| | Multiple Trauma | 1 | 2023 | 96 | 0.210 |
Why?
| | Tight Junction Proteins | 1 | 2022 | 9 | 0.210 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2022 | 73 | 0.200 |
Why?
| | Citrulline | 1 | 2022 | 40 | 0.200 |
Why?
| | Capillary Permeability | 1 | 2022 | 135 | 0.200 |
Why?
| | Dust | 1 | 2022 | 84 | 0.200 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 105 | 0.200 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 329 | 0.200 |
Why?
| | Hydrogen Peroxide | 1 | 2003 | 288 | 0.200 |
Why?
| | Mice, Inbred BALB C | 8 | 2006 | 1143 | 0.200 |
Why?
| | Endotoxins | 1 | 2022 | 211 | 0.190 |
Why?
| | Erythrocyte Transfusion | 1 | 2022 | 189 | 0.180 |
Why?
| | Plasma | 1 | 2022 | 211 | 0.180 |
Why?
| | Thrombosis | 1 | 2023 | 298 | 0.170 |
Why?
| | Cells, Cultured | 6 | 2016 | 3881 | 0.170 |
Why?
| | Complement Activation | 1 | 2022 | 340 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2022 | 447 | 0.160 |
Why?
| | Water | 1 | 2022 | 396 | 0.160 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 4 | 2006 | 260 | 0.160 |
Why?
| | Pilot Projects | 1 | 2022 | 1372 | 0.150 |
Why?
| | Male | 12 | 2023 | 55555 | 0.150 |
Why?
| | RNA, Messenger | 3 | 2022 | 2552 | 0.150 |
Why?
| | Nitric Oxide | 1 | 2022 | 823 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2006 | 398 | 0.140 |
Why?
| | Mice | 10 | 2016 | 14860 | 0.140 |
Why?
| | Transcription Factor RelA | 4 | 2014 | 82 | 0.140 |
Why?
| | Disease Models, Animal | 2 | 2023 | 3531 | 0.130 |
Why?
| | Endothelium, Vascular | 1 | 2022 | 843 | 0.130 |
Why?
| | Toll-Like Receptor 2 | 3 | 2005 | 110 | 0.130 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 144 | 0.130 |
Why?
| | Superoxides | 1 | 2006 | 214 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 1139 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 146 | 0.110 |
Why?
| | Lung Injury | 1 | 2016 | 197 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2005 | 164 | 0.110 |
Why?
| | Injury Severity Score | 1 | 2016 | 499 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 797 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1230 | 0.110 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 531 | 0.100 |
Why?
| | Interleukin-1beta | 1 | 2014 | 370 | 0.100 |
Why?
| | Cell Movement | 2 | 2017 | 868 | 0.100 |
Why?
| | Phospholipases A2, Secretory | 1 | 2012 | 23 | 0.100 |
Why?
| | Kringles | 2 | 2006 | 4 | 0.100 |
Why?
| | Urokinase-Type Plasminogen Activator | 2 | 2006 | 28 | 0.100 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2012 | 154 | 0.090 |
Why?
| | Protein Binding | 1 | 2016 | 1889 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 785 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 750 | 0.090 |
Why?
| | Mice, Knockout | 1 | 2016 | 2565 | 0.090 |
Why?
| | Cell Nucleus | 4 | 2017 | 554 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1313 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2016 | 3003 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2005 | 278 | 0.080 |
Why?
| | Peptidoglycan | 2 | 2005 | 25 | 0.080 |
Why?
| | Toll-Like Receptor 4 | 3 | 2005 | 287 | 0.070 |
Why?
| | Bronchioles | 1 | 2016 | 22 | 0.070 |
Why?
| | Toll-Like Receptors | 2 | 2004 | 167 | 0.070 |
Why?
| | Mice, Transgenic | 2 | 2006 | 1947 | 0.070 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 84 | 0.070 |
Why?
| | Drug Synergism | 2 | 2006 | 316 | 0.060 |
Why?
| | Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2005 | 13 | 0.060 |
Why?
| | Integrin alphaVbeta3 | 1 | 2005 | 20 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2012 | 795 | 0.060 |
Why?
| | I-kappa B Kinase | 3 | 2006 | 50 | 0.060 |
Why?
| | src Homology Domains | 1 | 2005 | 33 | 0.060 |
Why?
| | Up-Regulation | 2 | 2005 | 807 | 0.060 |
Why?
| | Protein Kinases | 2 | 2004 | 307 | 0.060 |
Why?
| | HMGB1 Protein | 1 | 2005 | 48 | 0.060 |
Why?
| | Chemokine CXCL2 | 1 | 2004 | 41 | 0.060 |
Why?
| | Transcription Factor AP-1 | 1 | 2003 | 80 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 71 | 0.050 |
Why?
| | Chemokines | 1 | 2004 | 216 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 594 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2003 | 267 | 0.050 |
Why?
| | Random Allocation | 1 | 2023 | 335 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 89 | 0.050 |
Why?
| | Blood Coagulation | 1 | 2023 | 218 | 0.050 |
Why?
| | Mitochondria | 1 | 2016 | 747 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 2 | 2006 | 110 | 0.050 |
Why?
| | Middle Aged | 2 | 2023 | 26719 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2005 | 2537 | 0.050 |
Why?
| | Adult | 2 | 2023 | 30528 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2177 | 0.040 |
Why?
| | Anticoagulants | 1 | 2023 | 550 | 0.040 |
Why?
| | Metabolomics | 1 | 2023 | 521 | 0.040 |
Why?
| | Interferon Regulatory Factor-1 | 1 | 2017 | 14 | 0.040 |
Why?
| | Chemokine CCL5 | 1 | 2017 | 45 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2003 | 1076 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 2017 | 64 | 0.040 |
Why?
| | Microcirculation | 1 | 2017 | 135 | 0.040 |
Why?
| | Chemotaxis | 1 | 2017 | 130 | 0.040 |
Why?
| | Phosphoserine | 1 | 2006 | 33 | 0.030 |
Why?
| | Paraquat | 1 | 2006 | 14 | 0.030 |
Why?
| | Leukocytes | 1 | 2017 | 276 | 0.030 |
Why?
| | Spleen | 1 | 2017 | 487 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 157 | 0.030 |
Why?
| | Female | 2 | 2023 | 59466 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 4894 | 0.030 |
Why?
| | Disease Progression | 1 | 2017 | 2380 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 442 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 396 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2017 | 1736 | 0.020 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 221 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 923 | 0.020 |
Why?
| | Rats | 1 | 2017 | 4958 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1147 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2635 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1226 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 1842 | 0.020 |
Why?
| | Protein Kinase C beta | 1 | 2005 | 24 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 2710 | 0.020 |
Why?
| | Protein Kinase C-alpha | 1 | 2005 | 41 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2004 | 52 | 0.010 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2004 | 20 | 0.010 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2004 | 41 | 0.010 |
Why?
| | alpha-Tocopherol | 1 | 2004 | 25 | 0.010 |
Why?
| | Enzyme Stability | 1 | 2004 | 62 | 0.010 |
Why?
| | I-kappa B Proteins | 1 | 2004 | 79 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1016 | 0.010 |
Why?
| | Acetylcysteine | 1 | 2004 | 141 | 0.010 |
Why?
| | Antibodies | 1 | 2005 | 371 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2004 | 477 | 0.010 |
Why?
| | Antioxidants | 1 | 2004 | 530 | 0.010 |
Why?
|
|
Sen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|